Private equity firm Perceptive Advisors led a $155m funding round in Kronos Bio, a private clinical-stage biopharmaceutical company, with participation from BlackRock, Casdin Partners, Commodore Capital, EcoR1 Capital, Fidelity Management and Research Company, Surveyor Capital, T. Rowe Price Associates, Woodline Partners, GV, Invus, Nextech Invest, Omega Funds, Polaris Partners, and Vida Ventures. "We appreciate the strong support from this group of investors and believe this capital will help propel Kronos through our upcoming period of clinical development," Norbert Bischofberger, Kronos Bio President and CEO.